WO2005060627A3 - Methods of assessing the risk of non-traumatic bone fracture - Google Patents

Methods of assessing the risk of non-traumatic bone fracture Download PDF

Info

Publication number
WO2005060627A3
WO2005060627A3 PCT/US2004/041489 US2004041489W WO2005060627A3 WO 2005060627 A3 WO2005060627 A3 WO 2005060627A3 US 2004041489 W US2004041489 W US 2004041489W WO 2005060627 A3 WO2005060627 A3 WO 2005060627A3
Authority
WO
WIPO (PCT)
Prior art keywords
risk
methods
rankl
bone fracture
assessing
Prior art date
Application number
PCT/US2004/041489
Other languages
French (fr)
Other versions
WO2005060627A2 (en
Inventor
Georg Schett
Stefan Kiechl
Johann Willeit
Original Assignee
Auxeris Therapeutics Inc
Georg Schett
Stefan Kiechl
Johann Willeit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auxeris Therapeutics Inc, Georg Schett, Stefan Kiechl, Johann Willeit filed Critical Auxeris Therapeutics Inc
Publication of WO2005060627A2 publication Critical patent/WO2005060627A2/en
Publication of WO2005060627A3 publication Critical patent/WO2005060627A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders

Abstract

The present invention relates to the identification of RANK ligand (RANKL) as associated with and useful as a marker of bone metabolism conditions and particularly of predicting risk of non-­traumatic bone fractures. The invention also relates to assays, methods and kits comprising RANKL and/or antibodies thereto for screening, diagnosis, prediction and monitoring. This invention provides methods for determining a subject's risk of non-traumatic bone fracture, comprising determining the subject's level of RANKL, particularly of soluble uncomplexed RANKL.
PCT/US2004/041489 2003-12-10 2004-12-10 Methods of assessing the risk of non-traumatic bone fracture WO2005060627A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52837703P 2003-12-10 2003-12-10
US60/528,377 2003-12-10

Publications (2)

Publication Number Publication Date
WO2005060627A2 WO2005060627A2 (en) 2005-07-07
WO2005060627A3 true WO2005060627A3 (en) 2005-09-09

Family

ID=34710079

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/041489 WO2005060627A2 (en) 2003-12-10 2004-12-10 Methods of assessing the risk of non-traumatic bone fracture

Country Status (1)

Country Link
WO (1) WO2005060627A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2434285A1 (en) * 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Breast cancer diagnostics
EP2433644A1 (en) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Breast cancer therapeutics
CN113484510A (en) * 2021-06-04 2021-10-08 浙江大学医学院附属邵逸夫医院 Standard curve quantification method for osteoclast inhibition degree of medicine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420016A (en) * 1992-03-24 1995-05-30 Serim Research Corporation Test device and kit for detecting helicobacter pylori

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420016A (en) * 1992-03-24 1995-05-30 Serim Research Corporation Test device and kit for detecting helicobacter pylori

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALVAREZ L. ET AL: "Serum Osteoprotegerin and Its Ligand in Paget's Disease of Bone.", ARTHRITIS & RHEUMATISM., vol. 48, no. 3, March 2003 (2003-03-01), pages 824 - 828, XP002988984 *
GRIMAUD E. ET AL: "Receptorn Activator of Nuclear Factor kB Ligand (RANKL)/Osteoprotegerin(OPG) Ratio is increased in Severe Osteolysis.", AMERICAN JOURNAL OF PATHOLOGY., vol. 163, no. 5, November 2003 (2003-11-01), pages 2024 - 2025, XP002988983 *

Also Published As

Publication number Publication date
WO2005060627A2 (en) 2005-07-07

Similar Documents

Publication Publication Date Title
DE60239470D1 (en) METHOD FOR EVALUATING PATHOLOGICAL ILLICIT STATES USING EXTRACELLULAR RNA
WO2005103719A3 (en) Using plasma proteomic pattern for diagnosis, classification, prediction of response to therapy and clinical behavior, stratification of therapy, and monitoring disease in hematologic malignancies
WO2005052592A3 (en) Methods for diagnosis, stratification, and monitoring of alzheimer’s disease
WO2004112589A3 (en) Method for the detection of gene transcripts in blood and uses thereof
WO2006036744A3 (en) Methods for a global assay of coagulation and fibrinolysis
WO2006074947A3 (en) METHODS AND ASSAYS FOR DISTINGUISHING BETWEEN DIFFERENT FORMS OF DISEASES AND DISORDERS CHARACTERIZED BY THROMBOCYTOPENIA AND/OR BY SPONTANEOUS INTERACTION BETWEEN VON WILLEBRAND FACTOR (vWF) AND PLATELETS
EP2293074A3 (en) Method for diagnosing neuro-degenerative disease
HK1101426A1 (en) Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
GB0510943D0 (en) Improved immunoassay methods
WO2006034427A3 (en) Diagnosis of fetal aneuploidy
WO2002085285A3 (en) Methods and reagents for regulating bone and cartilage formation
WO2008063479A3 (en) Pancreatic cancer biomarkers
WO2006055524A3 (en) Biomarkers for diagnosing schizophrenia and bipolar disorder
WO2004096985A3 (en) Methods for assessing biologic diversity
ATE451475T1 (en) METHODS AND SYSTEMS FOR DIAGNOSING DISEASES NOT AFFECTING THE CENTRAL NERVOUS SYSTEM (CNS) IN CNS SAMPLES
WO2006002240A8 (en) Computer systems and methods for constructing biological classifiers and uses thereof
AUPS293002A0 (en) Identification of oligosaccharides and their use in the diagnosis and evaluation of mucopolysaccharidoses and other related disorders
WO2006092729A3 (en) Novel biomarkers for diagnosis and/or prognosis or prognosis of neoplasias in animals
WO2007015113A3 (en) New protein isoforms of the pif-family and uses thereof
WO2004021008A3 (en) Methods for detecting breast and ovarian cancer
WO2005000875A3 (en) Compositions and methods comprising a ligand of chemerin receptor
WO2007079301A3 (en) Method of diagnosing a body weight condition or predisposition in an animal
WO2010033951A3 (en) Methods for identification and prediction of multiple sclerosis disease and therapy response
WO2005060627A3 (en) Methods of assessing the risk of non-traumatic bone fracture
WO2008072275A3 (en) Telematic system for using diagnostic reagent strips and method for acquiring calibration data

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase